Synthetic Genetic Systems for next generation biomedicines and bioprocesses
Overview
SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes.
Our philosophy is simple: all products and production processes are unique. Therefore core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for a specific purpose.
SynGenSys Technology Platform
Our platform technology harnesses years of research and development with bioindustrial partners. We engineer novel synthetic genetic parts from the ground-up, based on bioinformatic analysis of streams of genome-scale information pertinent to the biological system and user-defined design criteria.
Gene Therapy
DNA Engineering for Cell Type Specificity and Control: Gene and Cell Therapy
Transfer of therapeutic DNA or mRNA into human cells and tissues underpins many new strategies to treat disease. However, precise targeting and control of gene expression remains a fundamental challenge. Our design systems create novel libraries of cell-type specific promoters with a minimised DNA footprint that provide user-defined control of therapeutic transgene expression
Biopharmaceutical Manufacturing
DNA Engineering for Manufacturability: Biologics Production
Recombinant DNA constructs used to engineer a mammalian cell factory are at the core of a biomanufacturing process.
However, next generation protein biopharmaceuticals or gene therapies are inherently variable, can be difficult to manufacture and generic, one-size-fits-all genetic vectors cannot be optimal in all cases. Expanding the manufacturability design space, our platform creates new DNA parts that re-programme key synthetic processes to speed cellular production.
Expand your Manufacturability Solution Space
Genetic parts within a genetic assembly significantly influence the rate of multiple dynamic cellular processes (e.g. transcription, translation, transduction) that can affect product manufacturability. We envisage that the genetic vector does not have to be a "one-size-fits-all" single option, but can be designed to be product-specific using discrete combinations of synthetic parts.
Our Team
David James
Chief Scientific Officer
Adam Brown
Chief Technology Officer
Abayomi Johnson
Senior DNA Engineer
Renata Caikauskaite
Senior DNA Engineer
Clare Bowler
Administration Manager
Molly Smith
Cell Engineer
Pamela O’Neill
Cell Engineer
Join SynGenSys
We are a small, growing company at the interface of cell and molecular biology, informatics and engineering. We aim to create disruptive new solutions for design and manufacturing of next-generation medicines. If you have a passion for biological systems engineering and want to know more, contact us.
News
SynGenSys Ltd. and Takeda Ventures, Inc. announce a strategic collaboration aimed at the development of novel cell-type specific synthetic promoters to support development of Takeda’s pipeline of innovative cell and gene therapies.
Professor David James, Chief Scientific Officer of SynGenSys: “This is an incredibly exciting opportunity for SynGenSys. We will work closely with Takeda to design new synthetic DNA components that provide targeted and controlled expression of therapeutic transgenes only where they are needed, avoiding non-specific cytotoxicity in non-diseased cells and tissues”.
“Takeda has established a world-class network of collaborators including a research partnership with Syngensys, where we are jointly leveraging our expertise to construct precision targeted gene therapy,” said Dr Victor Stone, Senior Investment Director and Partner, Takeda Ventures Inc. “Our collaboration and investment in Syngensys enables Takeda’s capabilities in synthetic promoters to advance next-generation gene therapies.”.
7
Feb ’22
Contact
SynGenSys Ltd. 5th Floor, 3 St. Paul’s Place, 129 Norfolk Street, Sheffield S1 2JE, United Kingdom